Potentially Inappropriate Medication Use in Patients with Dementia

Citation: Yoon, K.; Kim, J.-T.; Kwack, W.-G.; Kim, D.; Lee, K.-T.; Yang, S.; Lee, S.; Choi, Y.-J.; Chung, E.-K. Potentially Inappropriate Medication Use in Patients with Dementia Int. J Environ. Res. Public Health 2022 , 19 , 11426. https://doi.org/10.3390/ ijerph 191811426 Academic Editor: Paul B. Tchounwou Received: 29 July 2022 Accepted: 8 September 2022 Published: 10 September 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations Copyright: © 2022 by the authors Licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/) International Journal of Environmental Research and Public Health Article Potentially Inappropriate Medication Use in Patients with Dementia Kyungwon Yoon 1,2,† , Jung-Tae Kim 3,† , Won-Gun Kwack 4,† , Donghyun Kim 1 , Kyung-Tae Lee 5,6 , Seungwon Yang 1,7 , Sangmin Lee 1,7, *, Yeo-Jin Choi 1,7, * and Eun-Kyoung Chung 1,3,7, * 1 Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea 2 Department of Pharmacy, Kyung Hee University Hospital, Seoul 02447, Korea 3 Department of Pharmacy, Kyung Hee University Hospital at Gangdong, Seoul 05278, Korea 4 Division of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital, Seoul 02447, Korea 5 Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Korea 6 Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea 7 Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Korea * Correspondence: leesm@khu.ac.kr (S.L.); yeojin.choi@khu.ac.kr (Y.-J.C.); cekchung@khu.ac.kr (E.-K.C.); Tel.: +82-2-961-2232 (S.L.); +82-2-961-0532 (Y.-J.C.); +82-2-961-2122 (E.-K.C.) † These authors contributed equally to this work Abstract: The objective of this study was to characterize the epidemiology of using potentially inappropriate medications associated with dementia exacerbation (DPIMs) in elderly outpatients with dementia. Electronic medical records were retrospectively reviewed for geriatric patients with dementia who were prescribed at least one medication in 2016 at a tertiary, university-affiliated hospital The 2015 Beers criteria were used to define DPIMs. Logistic regression was performed to identify factors associated with prescribing DPIMs in patients with dementia. Among 2100 patients included in our study, 987 (47.0%) patients were prescribed at least one DPIM. Benzodiazepines were the most frequently prescribed DPIM followed by anticholinergics, histamine H 2-receptor blockers, and zolpidem. The risk of prescribing DPIMs was significantly increased in female patients (odds ratio (OR) 1.355) with polypharmacy (OR 5.146) and multiple comorbidities (OR 1.129) ( p < 0.05 for all) Coexistence of Parkinson’s disease (OR 1.799), mood disorder (OR 1.373), or schizophrenia (OR 4.116) in patients with dementia further increased the likelihood of receiving DPIMs. In conclusion, DPIMs were commonly used in elderly patients with dementia in Korea with benzodiazepines most frequently prescribed followed by anticholinergics. Female patients using polypharmacy with multiple comorbidities should be closely monitored to minimize unnecessary DPIM use and, ultimately, DPIM-related harms Keywords: potentially inappropriate medication; geriatrics; dementia; Beers criteria; polypharmacy 1. Introduction As the global population ages, the proportion of individuals aged 65 years or older, defined as the geriatric population, has been exponentially and rapidly growing [ 1 ]. Aging is associated with substantial physiologic alterations, which makes elderly patients a vulnerable, special population for appropriate pharmacotherapy [ 2 – 4 ]. Advanced age is a risk factor for many chronic disorders including cardiovascular disease, diabetes mellitus, and neurological diseases; thus, the prevalence of chronic diseases is higher in geriatric patients, resulting in a subsequent increase in healthcare utilization and medication use [ 5 , 6 ]. One of the crucial concerns in geriatric pharmacotherapy is polypharmacy (i.e., ≥ 5 concomitant medications administered daily) [ 7 , 8 ]. The prevalence of polypharmacy among patients at the age of 65 years or older is at least 40% to 50%, potentially increasing the risk of Int. J. Environ. Res. Public Health 2022 , 19 , 11426. https://doi.org/10.3390/ijerph 191811426 https://www.mdpi.com/journal/ijerph

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 2 of 12 drug–drug interactions and consequent adverse outcomes such as repeated hospitalizations [ 7 , 9 , 10 ]. In addition to polypharmacy as well as multiple comorbidities in the elderly, physiologic alterations associated with aging itself contribute to pharmacokinetic and pharmacodynamic changes, leading to an increased risk for adverse drug events (ADEs) [ 7 , 11 ]. Therefore, appropriate medication use by thoroughly evaluating the benefits and risks of each drug is critical in elderly patients to improve treatment outcomes as well as to prevent ADEs In an effort for rational drug therapy, medications whose potential risk outweighs the potential benefits in the geriatric population were defined as potentially inappropriate medications (PIMs) [ 12 , 13 ]. One of the most commonly used criteria to identify PIMs for older people in clinical practice is Beers criteria which has been periodically updated and expanded by the American Geriatrics Society since its original development in 1991 [ 14 , 15 ]. Risks associated with using a PIM in the elderly include cognitive impairment, delirium, falls, and fractures, potentially leading to clinically significant harmful events such as hospitalizations, emergency department (ED) visits, and even death [ 12 , 16 ]. According to a previous retrospective study, use of at least one PIM substantially increases the likelihood of hospitalization and ED visits by 2.25- and 1.59-fold, respectively, in the elderly population [ 17 ]. However, PIMs have been frequently used in older individuals as suggested by previous studies reporting at least 40% to 50% of geriatric patients prescribed one or more PIM in clinical practice [ 16 , 18 , 19 ]. Dementia is one of the most common geriatric diseases with its prevalence rapidly increasing over the last couple of decades [ 20 , 21 ]. Although the etiology of dementia may differ among the patients, the majority of patients with dementia have multiple comorbidities such as depression and Parkinson’s disease, usually requiring treatment with multiple medications including PIMs [ 22 – 25 ]. As a result, patients with dementia might be at an increased risk of PIM-induced cognitive impairment such as impairments in language, working memory, and processing speed and other clinically significant events including increased risks of falls, physical dysfunction, and delirium [ 26 , 27 ], consequently contributing to increased mortality as well as accelerated disease progression as indicated by reduced scores of Mini-Mental State Examination (MMSE) [ 15 , 22 , 28 ]. Due to the substantial risk of certain PIMs in patients with dementia, the specific Beers criteria for dementia were developed based on the risk of drug-disease interaction that may exacerbate dementia as the pharmacokinetic and pharmacodynamic characteristics change with dementia progression [ 29 , 30 ]. According to a previous study evaluating the use of PIMs associated with dementia exacerbation (DPIMs) in eight European countries, 60% of patients with dementia were prescribed at least one PIM. However, little is known regarding DPIM use in patients with dementia in Korea. Considering the variability in demographic, clinical, and sociocultural aspects associated with drug therapy and disease states across different countries, specific data regarding the epidemiology of DPIMs in each country may be helpful for establishing optimal strategies to prevent excessive use of DPIMs [ 31 ]. Therefore, the aims of this study were to investigate the prevalence of using at least one DPIM for ambulatory patients with dementia of any cause in a tertiary, university-affiliated hospital in Korea and to identify factors associated with prescribing at least one DPIM in patients with dementia 2. Materials and Methods 2.1. Study Design This study was conducted by retrospectively reviewing electronic medical records (EMRs) of patients with dementia who had at least one documented outpatient prescription for systemic use from 1 January 2016 to 31 December 2016 at Kyung Hee University Hospital (Seoul, Korea), a tertiary academic medical center with 850 beds. Patients at the age of 65 years or older were included if they were diagnosed with dementia of any cause including Alzheimer’s disease based on the International Classification of Diseases (ICD-10). According to the ICD-10 codes, dementia was defined as the diagnostic code of F 00 (dementia in Alzheimer disease with late onset), F 01 (vascular dementia), F 02 (dementia

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 3 of 12 in other disease classified elsewhere including Creutzfeldt-Jakob disease, Huntington’s disease, Parkinson’s disease, and autoimmune or infection-related dementia), and F 03 (unspecified dementia) including all subcategories of each disease code [ 32 ]. This study was approved by the Institutional Review Board of Kyung Hee University Hospital (approval No.2017-07-068-004), and informed consents were exempted by the board 2.2. Data Collection, Definition, and Analyses The following demographic and clinical information was retrieved for each patient from EMRs: age; gender; comorbid conditions including Parkinson’s disease (G 20-22), mood (affective) disorders (F 30-39) such as bipolar disorder and depression, schizophrenia (F 20-29), and gastrointestinal disorders (K 20-31); prescribed medications; and duration of medication administration. In this study, DPIM was defined by the 2015 Beers criteria as PIMs in the elderly patients due to drug-disease interactions that may exacerbate dementia [ 15 ]. Drug classes included in this study as DPIMs were anticholinergics, benzodiazepines, histamine H 2-receptor antagonists (H 2 RAs), and nonbenzodiazepine/benzodiazepine receptor agonist hypnotics (i.e., zolpidem). Based on the formulary of our institution, medications defined as DPIMs are listed in Table 1 . Reasons for prescribing DPIMs were identified as the indicated comorbid condition using the ICD-10 codes based on the approved label for each DPIM. Patients prescribed 2 or more DPIMs were classified as multiple DPIM users considering substantially elevated risk of adverse health outcomes in patients who administered at least 2 PIMs [ 33 ]. The relative quantity of DPIM use in each patient was analyzed to assess the extent of DPIM usage in dementia management during the study period as considerable amount of DPIM usage makes patients susceptible to adverse outcomes [ 34 ] The relative quantity (%) of DPIM use over the study period was calculated as follows: Relative quantity of DPIM use ( % ) = h Number of DPIMs Dose × Number of doses Day × ( Total days of treatment ) i h Number of all medications Dose × Number of doses Day × ( Total days of treatment ) i × 100 Table 1. List of potentially inappropriate medications in elderly patients with dementia (DPIMs) based on the institutional formulary according to the 2015 Beers criteria Drugs with Strong Anticholinergic Properties Antidepressants Antihistamines Amitriptyline Amoxapine Clomipramine Imipramine Nortriptyline Paroxetine Chlorpheniramine Cyproheptadine Dimenhydrinate Hydroxyzine Triprolidine Antimuscarinics Antipsychotics Fesoterodine Oxybutynine Solifenacin Trospium Chlorpromazine Clozapine Olanzapine Perphenazine Antiparkinsonian Antispasmodics Benztropine Trihexyphenidyl Scopolamine

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 4 of 12 Table 1. Cont Drugs with Strong Anticholinergic Properties Benzodiazepines Alprazolam Bromazepam Chlordiazepoxide Clonazepam Clorazepate Clotiazepam Diazepam Etizolam Flurazepam Loflazepate Lorazepam Triazolam H 2 -receptor antagonists Cimetidine Famotidine Lafutidine Ranitidine Roxatidine Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics Zolpidem 2.3. Statistical Analysis All statistical analyses were performed using SPSS Statistic 23.0 (version 23.0; IBM SPSS Statistics for Windows, Armonk, NY, USA). Descriptive statistics were used to estimate the prevalence of DPIM use. Comparison between patients with at least one DPIM prescription and those who did not use any DPIM was performed utilizing Mann-Whitney U test for non-normally distributed continuous data, unpaired 2-tailed t test for normally distributed continuous data, and the χ 2 or Fisher’s exact test for categorical data. Normality for continuous variables was assessed by the Kolmogorov-Smirnov test In order to identify factors significantly associated with DPIM use, the univariate analysis was first performed for the following factors: age, sex, number of concurrent medications, number of comorbid diseases, and presence of each concomitant disease. Multiple logistic regression was then conducted using a stepwise forward method by examining the factors significantly associated with prescribing PIMs in patients with dementia in the univariate analysis. Odds ratios (ORs) with the corresponding 95% confidence intervals (CIs) were estimated, and any p -value < 0.05 was considered statistically significant 3. Results 3.1. Baseline Characteristics A total of 2100 patients with dementia satisfied the eligibility criteria of this study Baseline characteristics of patients included in this study are described in Table 2 . Overall, the majority of patients included in this study were females ( n = 1326; 63.1%). The median age of included patients was 77 years (interquartile range (IQR) of 73–81), and prevalent polypharmacy was observed with the median number of concurrent medications of 6 (IQR 3–9). All patients had at least one additional comorbid disease (IQR for the number of comorbid diseases, 3 to 7), most frequently mood disorder ( n = 740; 35.2%) followed by Parkinson’s disease ( n = 518; 24.7%) 3.2. Prevalence of DPIM Use Tables 2 and 3 summarize characteristics of DPIM users and the overall prevalence of DPIM use in our study patients, respectively. Among the 2100 patients included in our study, 987 (47.0%) patients were prescribed at least one DPIM. Compared to DPIM nonusers, DPIM users were more likely to be female patients, have more comorbidities, and use more concurrent medications (Table 2 ). Multiple DPIMs were prescribed to 432 (20.6%) patients (Table 3 ). The median relative quantity of DPIM use over all medications administered to dementia patients during the study period was 14.3% with an IQR of 8.1% to 24.2% The most frequently prescribed DPIM was a benzodiazepine ( n = 601; 28.6%) followed by

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 5 of 12 anticholinergics ( n = 555; 26.4%). H 2 RAs and zolpidem were prescribed to 146 (7.0%) and 92 (4.4%) patients, respectively Table 2. Baseline characteristics of patients included in this study a Characteristics DPIM Users ( n = 987) DPIM Non-Users ( n = 1113) Overall Patients ( n = 2100) p -Value b Age (years) 76 (73–80) 78 (73–82) 77 (73–81) <0.001 c Sex 0025 d Male [ n (%)] 339 (33.4) 435 (39.1) 774 (36.9) Female [ n (%)] 648 (65.7) 678 (60.9) 1326 (63.1) Number of concurrent medications 8 (6–11) 4 (2–6) 6 (3–9) <0.001 c Number of comorbid diseases 6 (4–8) 4 (2–6) 5 (3–7) <0.001 c Concomitant diseases Parkinson’s disease [ n (%)] 361 (36.6) 157 (14.1) 518 (24.7) <0.001 d Mood (affective) disorder e [ n (%)] 421 (42.7) 319 (28.7) 740 (35.2) <0.001 d Schizophrenic disorder f [ n (%)] 37 (3.7) 12 (1.1) 49 (2.3) <0.001 d Gastrointestinal disorder g [ n (%)] 228 (23.1) 179 (16.1) 407 (19.4) <0.001 d a Data presented as median (IQR) unless otherwise stated; b Comparison between DPIM users and non-users; c p value from Mann-Whitney U test; d p value from χ 2 test; e Includes bipolar and depressive disorders; f Includes schizophrenia, schizotypal, and delusional disorders; g Includes diseases of esophagus, stomach, and duodenum 3.3. Prevalence of DPIM Use Tables 2 and 3 summarize characteristics of DPIM users and the overall prevalence of DPIM use in our study patients, respectively. Among the 2100 patients included in our study, 987 (47.0%) patients were prescribed at least one DPIM. Compared to DPIM nonusers, DPIM users were more likely to be female patients, have more comorbidities, and use more concurrent medications (Table 2 ). Multiple DPIMs were prescribed to 432 (20.6%) patients (Table 3 ). The median relative quantity of DPIM use over all medications administered to dementia patients during the study period was 14.3% with an IQR of 8.1% to 24.2% The most frequently prescribed DPIM was a benzodiazepine ( n = 601; 28.6%) followed by anticholinergics ( n = 555; 26.4%). H 2 RAs and zolpidem were prescribed to 146 (7.0%) and 92 (4.4%) patients, respectively Table 3. Prevalence of DPIM use in the study population ( n = 2100) Characteristics Number (%) Unless Otherwise Stated Patients with ≥ 1 DPIM prescription 987 (47.0) Patients with ≥ 2 DPIM prescriptions 432 (20.6) 2 DPIMs 288 (13.7) 3 DPIMs 96 (4.6) 4 DPIM 31 (1.5) ≥ 5 DPIMs 17 (0.8) Relative quantity of DPIM use (%, median [IQR]) 14.3 [8.1–24.2] Type of DPIMs Anticholinergics a 555 (26.4) Benzodiazepines 601 (28.6) H 2-receptor antagonists 146 (7.0) Zolpidem 92 (4.4) a Drugs with strong anticholinergic properties as listed in Table 1 .

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 6 of 12 3.4. Factors Associated with DPIM Use The univariate analysis showed significant association of DPIM use with sex; age; polypharmacy use; number of comorbid diseases; and the presence of Parkinson’s disease, mood disorder, schizophrenia, and gastrointestinal disorder ( p < 0.05, Table 4 ). Based on the multivariate regression analysis, DPIMs were more likely to be prescribed in the following (Table 4 ): female patients (OR 1.355, 95% CI 1.103–1.664, p = 0.004), individuals using polypharmacy (OR 5.146, 95% CI 3.912–6.768, p < 0.001), patients with multiple comorbidities (OR 1.129 for each one additional comorbid disease, 95% CI 1.073–1.188, p < 0.001), those with Parkinson’s disease (OR 1.799, 95% CI 1.416–2.286, p < 0.001), those with mood disorder (OR 1.373, 95% CI 1.111–1.695, p < 0.001), and those with schizophrenia (OR 4.116, 95% CI 1.959–8.648, p < 0.001) Table 4. Univariate and multivariate analyses for the association between DPIM use and patient characteristics Patient Characteristics Univariate Analysis Multivariate Analysis OR (95% CI) p -Value OR (95% CI) p -Value Female sex 1.226 (1.026–1.466) 0.025 1.355 (1.103–1.664) 0.004 Age 0.969 (0.956–0.983) <0.001 0.989 (0.973–1.005) 0.181 Polypharmacy use a 8.881 (7.110–11.093) <0.001 5.146 (3.912–6.768) <0.001 Number of comorbid diseases 1.385 (1.332–1.440) <0.001 1.129 (1.073–1.188) <0.001 Presence of: Parkinson’s disease 3.511 (2.839–4.344) <0.001 1.799 (1.416–2.286) <0.001 Mood (affective) disorder b 1.851 (1.545–2.219) <0.001 1.373 (1.111–1.695) <0.001 Schizophrenia 3.573 (1.853–6.892) <0.001 4.116 (1.959–8.648) <0.001 Gastrointestinal disorder 1.567 (1.261–1.949) <0.001 0.845 (0.651–1.099) 0.209 a Number of concurrent medications ≥ 5; b Include bipolar and depressive disorders 4. Discussion We evaluated the prevalence and risk factors of prescribing DPIMs in patients with dementia over one year at a tertiary academic medical center in Korea. The prevalence of using PIMs possibly exacerbating cognitive function in patients with dementia was relatively high (47%) (Tables 2 and 3 ). All patients included in our study took multiple medications (Table 2 ), and one in seven medications was a DPIM (Table 3 ). Moreover, the median relative quantity of DPIM use during the study period in our study population was 14.3% (IQR 8.1–24.3). The relative quantity of DPIM use escalated with advancing age, with the highest quantity prescribed to patients over 80 years of age; this suggests DPIMs commonly prescribed to patients with dementia. Furthermore, more than one in five patients included in our current study were prescribed multiple DPIMs (Table 3 ), which might further increase the risk of exacerbating dementia [ 35 , 36 ]. Our current study findings are consistent with previous studies suggesting a relatively high frequency of using PIMs in patients with neuropsychiatric comorbidities including dementia as well as epilepsy, depression, delirium, insomnia, and Parkinson’s disease [ 37 , 38 ]. This is of crucial concern in patients with dementia because multiple neuropsychiatric diseases frequently coexist in these patients, and several medications commonly used to treat these disorders are considered DPIMs based on the Beers criteria. This high prevalence of DPIM use in a relatively large quantity (Table 3 ) might result from insufficient knowledge of clinicians in geriatric pharmacotherapy and extremely busy clinical setting which significantly limits time commitment to appropriate medication therapy [ 39 , 40 ]. Considering the rapid increase in the global prevalence of dementia projected to be >15% of geriatric patients by 2050 [ 31 ], DPIM use might further accelerate dementia progression [ 35 , 36 , 41 ], contributing to substantial dementia-related burden to the society as well as to the healthcare systems.

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 7 of 12 In this study, DPIMs were more likely to be prescribed to female patients with multiple comorbid diseases using polypharmacy (Table 4 ). Consistent with our present study, previous studies suggested a higher likelihood of using PIMs in female geriatric patients including those with dementia [ 10 , 42 , 43 ], possibly associated with sex-related comorbidities [ 44 – 46 ]. Compared to males, female patients are more vulnerable to developing anxiety, insomnia, incontinence, depression, and other mood disorders [ 16 , 47 , 48 ]. These are common indications for using benzodiazepines, hypnotics, and anticholinergics, which are listed as DPIMs based on the Beers criteria [ 15 ]. Similar to previous studies [ 16 , 49 – 54 ], polypharmacy was a significant risk factor for prescribing PIMs in patients with dementia, possibly due to the presence of certain comorbidities associated with polypharmacy such as Parkinson’s disease, mood (affective) disorder, and schizophrenia. Thus, patients with dementia requiring multiple medications for treatment of comorbidities should be more closely monitored. Notably, female sex, polypharmacy, and multiple comorbidities are known risk factors of dementia progression [ 46 , 55 , 56 ]. This might imply the risk of dementia progression in female patients using five or more medications to treat multiple concomitant diseases might be attributed to DPIM usages [ 57 , 58 ]. Future studies are warranted for effective medication management including medication reconciliation and deprescribing to prevent rapid progression of dementia as well as to reduce potential harms caused by PIMs in elderly patients with dementia in the real-world setting Our current study suggested benzodiazepines as the most commonly prescribed DPIM class in patients with dementia, followed by anticholinergics (Table 3 ). Zolpidem was the most frequently used DPIM as a single agent. These medications are commonly prescribed to manage various comorbid conditions in patients with dementia including anxiety, agitation, delirium, insomnia, psychosis, and Parkinsonism [ 59 – 62 ]. Consistently, our present study showed a significantly increased risk of prescribing DPIMs in the presence of these comorbidities, i.e., Parkinson’s disease, mood (affective) disorder, and schizophrenia (Table 4 ). Benzodiazepines, anticholinergics, and zolpidem may cause cognitive impairment, falls, and fractures, potentially contributing to mortality and morbidity associated with these drugs [ 9 , 63 – 66 ]. The risk for ADEs associated with benzodiazepines, anticholinergics, and zolpidem is especially high in geriatric patients due to increased pharmacodynamic sensitivity to these medications as well as decreased pharmacokinetic elimination of these drugs with aging [ 67 ]. This is of particular concern in patients with dementia due to adverse effects of benzodiazepines, zolpidem, and anticholinergics on cognitive function, potentially resulting in accelerated dementia progression [ 15 , 68 – 71 ]. In addition, recent studies suggested benzodiazepines and zolpidem induce significant non-cognitive functional decline attributed to pneumonia and hip fractures in patients with dementia, substantially elevating the risk of morbidity and mortality [ 72 – 75 ]. Nonetheless, the global prevalence of using benzodiazepines, anticholinergics, and zolpidem in elderly patients is still high [ 16 , 47 , 59 , 76 – 78 ], accounting for >25% of all PIM usages. Systematic interventions are urgently needed in clinical practice for promoting awareness of appropriate geriatric pharmacotherapy as well as implementing inter-professional medication review and management to avoid unnecessary DPIM use in patients with dementia In contrast, gastrointestinal disorders were not significantly associated with DPIM use (Table 4 ). Among our study patients with gastrointestinal disorders ( n = 407; 19.4%), H 2 RAs were prescribed to only approximately one third of them ( n = 146; 7.0%) (Tables 2 and 3 ). Gastrointestinal disorders are common indications for H 2 RA use; however, the availability of therapeutic alternatives to H 2 RAs including proton pump inhibitors (PPIs) and potassium-competitive acid blockers (i.e., prazans) might account for the relatively low rate of H 2 RA use among study patients as well as the lack of association between gastrointestinal disorders and DPIM use [ 79 ]. This suggests the majority of patients with gastrointestinal disorders receive alternative therapy other than H 2 RAs. In the 2015 Beers criteria, H 2 RAs were listed as DPIMs to avoid in elderly patients with dementia because of the risk of cognitive decline [ 15 , 70 , 80 ]. However, recent studies suggested the lack of strong evidence for the association between H 2 RAs and impaired cognitive function [ 70 , 81 ];

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 8 of 12 most of the H 2 RA adverse effects on the central nervous system such as cognitive impairment and delirium occur at supratherapeutic doses, particularly in patients with reduced kidney function receiving conventional doses not adjusted for the renal function [ 70 ]. Furthermore, some studies suggested increased risk of cognitive impairment or dementia progression with PPI use [ 82 ]; therefore, considering adverse outcomes such as increased risk of fractures and infections, chronic PPI use in the elderly may not be a favorable treatment option [ 83 ].Therefore, H 2 RAs were removed from the DPIM list in the 2019 updated Beers criteria due to weak evidence on H 2 RA-induced cognitive impairment, thereby avoiding excessively limited therapeutic options for the elderly dementia patients with gastrointestinal diseases [ 70 ]. However, the updated Beers criteria still recommends dosage reduction in patients with renal insufficiency to avoid mental status changes [ 70 ]. There are some study limitations to be addressed. First, this was a single-center, retrospective study conducted by reviewing outpatient EMRs over the period of one year in 2016. Considering the variability in medication use across different practice sites as well as different countries along with the updated Beers criteria in 2019, caution should be exercised when interpreting and generalizing our study findings. In addition, due to the retrospective nature of this study based on outpatient EMRs, our study results were primarily dependent on documented clinical data in the EMR. For the same reason, we classified Parkinson’s disease as a separate comorbidity in patients with Parkinson’s disease dementia despite strong association between Parkinson’s disease and Parkinson’s disease dementia. Additionally, benzodiazepines are commonly prescribed to patients with various psychiatric disorders including insomnia and anxiety. However, they were frequently prescribed in dementia without separate diagnostic codes for insomnia or anxiety as they are common presenting symptoms in dementia. In this study, the majority of our patients did not have those separate diagnostic codes for benzodiazepine use. Hence, other clinical indications for benzodiazepine use than dementia could not be recorded in this study. Furthermore, appropriateness of antipsychotics without strong anticholinergic activity as well as other undocumented comorbid diseases that might have contributed to DPIM were not assessed. According to the Beers criteria, antipsychotic use in patients with dementia is generally considered inappropriate due to the risk of stroke and mortality [ 15 , 70 ]. However, antipsychotics without strong anticholinergic activity may be considered appropriate if nonpharmacologic therapy has failed or is not feasible and the patient is substantial threat to self or others [ 15 , 70 ]. Despite comprehensive EMR review, only limited information was available to determine the appropriateness of using antipsychotics without strong anticholinergic activity in our present study. Lastly, outcomes on progressive cognitive impairment associated with DPIM use were not evaluated owing to the lack of sufficient information documented in the EMR. Nonetheless, our current study might contribute to the current body of literature regarding epidemiological features of PIM use in dementia using EMR-based real-world data including medications often prescribed without insurance reimbursement in Korea (e.g., benzodiazepines, zolpidem) Further research investigating clinical outcomes associated with using DPIMs including antipsychotics with a larger sample size is warranted to optimize pharmacotherapy in geriatric patients, particularly those with dementia 5. Conclusions In conclusion, the prevalence of DPIM use in elderly patients with dementia was high in Korea. Approximately half of the patients with dementia received at least one DPIM with multiple DPIMs frequently used in these patients. Benzodiazepines were most commonly prescribed, followed by anticholinergics, H 2 RAs, and zolpidem. Overall, DPIMs were more likely to be prescribed in female patients using polypharmacy with multiple comorbidities, particularly Parkinson’s disease, mood disorder, and schizophrenia. Therefore, implementation of evidence-based public health policy as well as system-wide interventions such as close patient monitoring, medication reconciliation, and medication therapy manage-

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 9 of 12 ment should be considered to minimize unnecessary DPIM use and ultimately, to prevent potential harms associated with DPIM use in geriatric patients with dementia Author Contributions: Conceptualization, K.Y., J.-T.K., W.-G.K., K.-T.L. and E.-K.C.; methodology, K.Y., J.-T.K., W.-G.K., S.L., Y.-J.C. and E.-K.C.; software, D.K. and S.Y.; validation, K.Y., J.-T.K., W.-G.K., S.L., Y.-J.C. and E.-K.C.; formal analysis, D.K., S.Y., Y.-J.C. and E.-K.C.; investigation, K.-T.L., S.L., Y.-J.C. and E.-K.C.; resources, S.L., Y.-J.C. and E.-K.C.; data curation, K.Y., J.-T.K. and W.-G.K.; writing—original draft preparation, K.Y., J.-T.K., W.-G.K., S.L., Y.-J.C. and E.-K.C.; writing—review and editing, K.-T.L., S.L., Y.-J.C. and E.-K.C.; visualization, D.K. and S.Y.; supervision, S.L., Y.-J.C. and E.-K.C.; project administration, S.L., Y.-J.C. and E.-K.C.; funding acquisition, Y.-J.C. and E.-K.C. All authors have read and agreed to the published version of the manuscript Funding: This research was supported by a grant (No. 21153 MFDS 601-1) from the Ministry of Food and Drug Safety Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Kyung Hee University Hospital (approval No. 2017-07-068-004) Informed Consent Statement: Patient consent was waived by the board due to use of anonymized patient data Data Availability Statement: The datasets generated and/or analyzed during the current study are not publicly available due to the inclusion of private medical information but may be available from the corresponding author upon reasonable request Conflicts of Interest: The authors declare no conflict of interest References 1 United Nations. World Population Ageing 2019 Highlights. Available online: https://www.un.org/en/development/desa/ population/publications/pdf/ageing/WorldPopulationAgeing 2019-Highlights.pdf (accessed on 6 July 2022) 2 Waisel, D.B. Vulnerable populations in healthcare Curr. Opin. Anaesthesiol 2013 , 26 , 186–192. [ CrossRef ] 3 World Health Organization. Ageing and Health. 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/ ageing-and-health (accessed on 4 June 2022) 4 Mangoni, A.A.; Jackson, S.H. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications Br. J. Clin. Pharmacol 2004 , 57 , 6–14. [ CrossRef ] 5 Zayas, C.E.; He, Z.; Yuan, J.; Maldonado-Molina, M.; Hogan, W.; Modave, F.; Guo, Y.; Bian, J. Examining healthcare utilization patterns of elderly middle-aged adults in the United States Proc. Int. Fla. AI Res. Soc. Conf 2016 , 2016 , 361–366 6 Prasad, S.; Sung, B.; Aggarwal, B.B. Age-associated chronic diseases require age-old medicine: Role of chronic inflammation Prev. Med 2012 , 54 , S 29–S 37. [ CrossRef ] 7 Halli-Tierney, A.D.; Scarbrough, C.; Carroll, D. Polypharmacy: Evaluating risks and deprescribing Am. Fam. Physician 2019 , 100 , 32–38 8 Morin, L.; Johnell, K.; Laroche, M.L.; Fastbom, J.; Wastesson, J.W. The epidemiology of polypharmacy in older adults: Registerbased prospective cohort study Clin. Epidemiol 2018 , 10 , 289–298. [ CrossRef ] 9 D í az-Guti é rrez, M.J.; Mart í nez-Cengotitabengoa, M.; S á ez de Adana, E.; Cano, A.I.; Mart í nez-Cengotitabengoa, M.T.; Besga, A.; Segarra, R.; Gonz á lez-Pinto, A. Relationship between the use of benzodiazepines and falls in older adults: A systematic review Maturitas 2017 , 101 , 17–22. [ CrossRef ] 10 Chang, T.I.; Park, H.; Kim, D.W.; Jeon, E.K.; Rhee, C.M.; Kalantar-Zadeh, K.; Kang, E.W.; Kang, S.W.; Han, S.H. Polypharmacy, hospitalization, and mortality risk: A nationwide cohort study Sci. Rep 2020 , 10 , 18964. [ CrossRef ] 11 Sera, L.C.; McPherson, M.L. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy Clin. Geriatr. Med 2012 , 28 , 273–286. [ CrossRef ] 12 Zhang, X.; Zhou, S.; Pan, K.; Li, X.; Zhao, X.; Zhou, Y.; Cui, Y.; Liu, X. Potentially inappropriate medications in hospitalized older patients: A cross-sectional study using the Beers 2015 criteria versus the 2012 criteria Clin. Interv. Aging 2017 , 12 , 1697–1703 [ CrossRef ] 13 Niehoff, K.M.; Mecca, M.C.; Fried, T.R. Medication appropriateness criteria for older adults: A narrative review of criteria and supporting studies Ther. Adv. Drug Saf 2019 , 10 , 2042098618815431. [ CrossRef ] [ PubMed ] 14 Beers, M.H.; Ouslander, J.G.; Rollingher, I.; Reuben, D.B.; Brooks, J.; Beck, J.C. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine Arch. Intern. Med 1991 , 151 , 1825–1832 [ CrossRef ] [ PubMed ] 15 American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults J. Am. Geriatr. Soc 2015 , 63 , 2227–2246. [ CrossRef ] [ PubMed ]

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 10 of 12 16 Roux, B.; Sirois, C.; Simard, M.; Gagnon, M.E.; Laroche, M.L. Potentially inappropriate medications in older adults: A populationbased cohort study Fam. Pract 2020 , 37 , 173–179. [ CrossRef ] 17 Jeon, H.L.; Park, J.; Han, E.; Kim, D.S. Potentially inappropriate medication and hospitalization/emergency department visits among the elderly in Korea Int. J. Qual. Health Care 2018 , 30 , 50–56. [ CrossRef ] 18 Zhang, H.; Wong, E.L.Y.; Wong, S.Y.S.; Chau, P.Y.K.; Yip, B.H.K.; Chung, R.Y.N.; Lee, E.K.P.; Lai, F.T.T.; Yeoh, E.-K. Prevalence and determinants of potentially inappropriate medication use in Hong Kong older patients: A cross-sectional study BMJ Open 2021 , 11 , e 051527. [ CrossRef ] 19 Awad, A.; Hanna, O. Potentially inappropriate medication use among geriatric patients in primary care setting: A cross-sectional study using the Beers, STOPP, FORTA and MAI criteria PLoS ONE 2019 , 14 , e 0218174. [ CrossRef ] 20 Arvanitakis, Z.; Shah, R.C.; Bennett, D.A. Diagnosis and Management of Dementia: Review JAMA 2019 , 322 , 1589–1599 [ CrossRef ] 21 Korean Statistial Information Service (KOSIS). Disease Category Resultig in Hospitalization of 65 Years of Age and Older Elderly Available online: https://kosis.kr/statHtml/statHtml.do?orgId=350&tblId=DT_35001_A 667418&conn_path=I 2 (accessed on 4 June 2022) 22 Renom-Guiteras, A.; Thürmann, P.A.; Miralles, R.; Klaaßen-Mielke, R.; Thiem, U.; Stephan, A.; Bleijlevens, M.H.C.; Jolley, D.; Leino-Kilpi, H.; Rahm Hallberg, I.; et al. Potentially inappropriate medication among people with dementia in eight European countries Age Ageing 2018 , 47 , 68–74. [ CrossRef ] 23 Ismail, Z.; Malick, A.; Smith, E.E.; Schweizer, T.; Fischer, C. Depression versus dementia: Is this construct still relevant? Neurodegener. Dis. Manag 2014 , 4 , 119–126. [ CrossRef ] 24 Hukins, D.; Macleod, U.; Boland, J.W. Identifying potentially inappropriate prescribing in older people with dementia: A systematic review Eur. J. Clin. Pharmacol 2019 , 75 , 467–481. [ CrossRef ] [ PubMed ] 25 Delgado, J.; Bowman, K.; Clare, L. Potentially inappropriate prescribing in dementia: A state-of-the-art review since 2007 BMJ Open 2020 , 10 , e 029172. [ CrossRef ] [ PubMed ] 26 Liu, L.; Jia, L.; Jian, P.; Zhou, Y.; Zhou, J.; Wu, F.; Tang, Y. The effects of benzodiazepine use and abuse on cognition in the elders: A systematic review and meta-analysis of comparative studies Front. Psychiatry 2020 , 11 , 007555. [ CrossRef ] [ PubMed ] 27 Fox, C.; Smith, T.; Maidment, I.; Chan, W.Y.; Bua, N.; Myint, P.K.; Boustani, M.; Kwok, C.S.; Glover, M.; Koopmans, I.; et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: A systematic review Age Ageing 2014 , 43 , 604–615. [ CrossRef ] 28 Fox, C.; Richardson, K.; Maidment, I.D.; Savva, G.M.; Matthews, F.E.; Smithard, D.; Coulton, S.; Katona, C.; Boustani, M.A.; Brayne, C. Anticholinergic medication use and cognitive impairment in the older population: The medical research council cognitive function and ageing study J. Am. Geriatr. Soc 2011 , 59 , 1477–1483. [ CrossRef ] 29 American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults J. Am. Geriatr Soc 2012 , 60 , 616–631. [ CrossRef ] 30 Reeve, E.; Trenaman, S.C.; Rockwood, K.; Hilmer, S.N. Pharmacokinetic and pharmacodynamic alterations in older people with dementia Expert Opin. Drug Metab. Toxicol 2017 , 13 , 651–668. [ CrossRef ] 31 Shon, C.; Yoon, H. Health-economic burden of dementia in South Korea BMC Geriatr 2021 , 21 , 549. [ CrossRef ] 32 Centers for Disease Control and Prevention (CDC). ICD-10. Available online: https://www.cdc.gov/nchs/icd/icd 10.htm (accessed on 8 May 2022) 33 Xing, X.X.; Zhu, C.; Liang, H.Y.; Wang, K.; Chu, Y.Q.; Zhao, L.B.; Jiang, C.; Wang, Y.Q.; Yan, S.Y. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: A systematic review and meta-analysis Ann. Pharmacother 2019 , 53 , 1005–1019. [ CrossRef ] 34 Wang, T.C.; Ku, P.J.; Lu, H.L.; Hsu, K.C.; Trezise, D.; Wang, H.Y. Association between potentially inappropriate medication use and chronic diseases in the elderly Int. J. Environ. Res. Public Health 2019 , 16 , 2189. [ CrossRef ] 35 Ramsey, C.M.; Gnjidic, D.; Agogo, G.O.; Allore, H.; Moga, D. Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis Alzheimers Dement 2018 , 4 , 1–10. [ CrossRef ] [ PubMed ] 36 Vickers, L.E.; Martinez, A.I.; Wallem, A.M.; Johnson, C.; Moga, D.C. Potentially inappropriate medication use in older adults with Alzheimer’s disease and related dementias living in the community: A cross-sectional analysis Drugs—Real World Outcomes 2021 , 8 , 519–526. [ CrossRef ] 37 Nam, Y.-S.; Han, J.S.; Kim, J.Y.; Bae, W.K.; Lee, K. Prescription of potentially inappropriate medication in Korean older adults based on 2012 Beers Criteria: A cross-sectional population based study BMC Geriatr 2016 , 16 , 118. [ CrossRef ] 38 Seo, M.K.; Bae, M.K.; Lee, L.H.; Jeon, S.; Yoon, J.H. Assessment of potentially inappropriate medication use in Korean elderly pateints with Parkinson’ Disease Korea J. Clin. Pharm 2015 , 25 , 254–263 39 Jungo, K.T.; Streit, S.; Lauffenburger, J.C. Patient factors associated with new prescribing of potentially inappropriate medications in multimorbid US older adults using multiple medications BMC Geriatr 2021 , 21 , 163. [ CrossRef ] 40 Lavan, A.H.; Gallagher, P.F.; O’Mahony, D. Methods to reduce prescribing errors in elderly patients with multimorbidity Clin Interv. Aging 2016 , 11 , 857–866 41 Machado-Duque, M.E.; Valladales-Restrepo, L.F.; Ospina-Cano, J.A.; Londoño-Serna, M.J.; Machado-Alba, J.E. Potentially inappropriate prescriptions of antipsychotics for patients with dementia Front. Pharmacol 2021 , 12 , 695315. [ CrossRef ]

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 11 of 12 42 Morgan, S.G.; Weymann, D.; Pratt, B.; Smolina, K.; Gladstone, E.J.; Raymond, C.; Mintzes, B. Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults Age Ageing 2016 , 45 , 535–542. [ CrossRef ] 43 Guaraldo, L.; Cano, F.G.; Damasceno, G.S.; Rozenfeld, S. Inappropriate medication use among the elderly: A systematic review of administrative databases BMC Geriatr 2011 , 11 , 79. [ CrossRef ] 44 Podcasy, J.L.; Epperson, C.N. Considering sex and gender in Alzheimer disease and other dementias Dialogues Clin. Neurosci 2016 , 18 , 437–446. [ CrossRef ] 45 Beam, C.R.; Kaneshiro, C.; Jang, J.Y.; Reynolds, C.A.; Pedersen, N.L.; Gatz, M. Differences between women and men in incidence rates of dementia and Alzheimer’s disease J. Alzheimers Dis 2018 , 64 , 1077–1083. [ CrossRef ] [ PubMed ] 46 Anstey, K.J.; Peters, R.; Mortby, M.E.; Kiely, K.M.; Eramudugolla, R.; Cherbuin, N.; Huque, M.H.; Dixon, R.A. Association of sex differences in dementia risk factors with sex differences in memory decline in a population-based cohort spanning 20–76 years Sci. Rep 2021 , 11 , 7710. [ CrossRef ] [ PubMed ] 47 Torres-Bondia, F.; de Batlle, J.; Galv á n, L.; Buti, M.; Barb é , F.; Piñol-Ripoll, G. Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015 BMC Public Health 2020 , 20 , 818. [ CrossRef ] [ PubMed ] 48 Centers for Disease Control and Prevention. Antidepressant Use among Adults: United States, 2015–2018. Available online: https://www.cdc.gov/nchs/products/databriefs/db 377.htm (accessed on 19 July 2022) 49 Kristensen, R.U.; Nørgaard, A.; Jensen-Dahm, C.; Gasse, C.; Wimberley, T.; Waldemar, G. Polypharmacy and potentially inappropriate medication in people with dementia: A nationwide study J. Alzheimers Dis 2018 , 63 , 383–394. [ CrossRef ] [ PubMed ] 50 Growdon, M.E.; Gan, S.; Yaffe, K.; Steinman, M.A. Polypharmacy among older adults with dementia compared with those without dementia in the United States J. Am. Geriatr. Soc 2021 , 69 , 2464–2475. [ CrossRef ] [ PubMed ] 51 Poblador-Plou, B.; Calder ó n-Larrañaga, A.; Marta-Moreno, J.; Hancco-Saavedra, J.; Sicras-Mainar, A.; Soljak, M.; Prados-Torres, A Comorbidity of dementia: A cross-sectional study of primary care older patients BMC Psychiatry 2014 , 14 , 84. [ CrossRef ] 52 Mueller, C.; Molokhia, M.; Perera, G.; Veronese, N.; Stubbs, B.; Shetty, H.; Codling, D.; Huntley, J.; Stewart, R. Polypharmacy in people with dementia: Associations with adverse health outcomes Exp. Gerontol 2018 , 106 , 240–245. [ CrossRef ] 53 Lim, Y.-J.; Kim, H.-Y.; Choi, J.; Lee, J.S.; Ahn, A.-L.; Oh, E.-J.; Cho, D.-Y.; Kweon, H.-J. Potentially inappropriate medications by Beers Criteria in older outpatients: Prevalence and risk factors Korean J. Fam. Med 2016 , 37 , 329–333. [ CrossRef ] 54 Abdulah, R.; Insani, W.N.; Destiani, D.P.; Rohmaniasari, N.; Mohenathas, N.D.; Barliana, M.I. Polypharmacy leads to increased prevalence of potentially inappropriate medication in the Indonesian geriatric population visiting primary care facilities Ther Clin. Risk Manag 2018 , 14 , 1591–1597. [ CrossRef ] 55 Park, H.Y.; Park, J.W.; Song, H.J.; Sohn, H.S.; Kwon, J.W. The association between polypharmacy and dementia: A nested case-control study based on a 12-year longitudinal cohort database in South Korea PLoS ONE 2017 , 12 , e 0169463. [ CrossRef ] 56 Santiago, J.A.; Potashkin, J.A. The impact of disease comorbidities in Alzheimer’s disease Front. Aging Neurosci 2021 , 13 , 631770 [ CrossRef ] [ PubMed ] 57 Trenaman, S.C.; Rideout, M.; Andrew, M.K. Sex and gender differences in polypharmacy in persons with dementia: A scoping review SAGE Open Med 2019 , 7 , 2050312119845715. [ CrossRef ] [ PubMed ] 58 Thapaliya, K.; Harris, M.L.; Byles, J.E. Polypharmacy trajectories among older women with and without dementia: A longitudinal cohort study Explor. Res. Clin. Soc. Pharm 2021 , 3 , 100053. [ CrossRef ] [ PubMed ] 59 Hwang, S.-H.; Han, S.; Choi, H.; Park, C.; Kim, S.M.; Kim, T.H. Trends in the prescription of benzodiazepines for the elderly in Korea BMC Psychiatry 2017 , 17 , 303. [ CrossRef ] [ PubMed ] 60 Bogunovic, O.J.; Greenfield, S.F. Practical geriatrics: Use of benzodiazepines among elderly patients Psychiatr. Serv 2004 , 55 , 233–235. [ CrossRef ] 61 Simon, G.E.; Ludman, E.J. Outcome of new benzodiazepine prescriptions to older adults in primary care Gen. Hosp. Psychiatry 2006 , 28 , 374–378. [ CrossRef ] 62 Oh, T.K.; Park, H.Y.; Song, I.-A. Benzodiazepine use and long-term mortality in South Korean adult population: A cohort study Yonsei Med. J 2021 , 62 , 528–534. [ CrossRef ] 63 Davies, S.J.; Rudoler, D.; de Oliveira, C.; Huang, A.; Kurdyak, P.; Iaboni, A. Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study J. Psychopharmacol 2022 , 36 , 460–469. [ CrossRef ] 64 Ruxton, K.; Woodman, R.J.; Mangoni, A.A. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis Br. J. Clin. Pharmacol 2015 , 80 , 209–220. [ CrossRef ] 65 Kang, D.Y.; Park, S.; Rhee, C.W.; Kim, Y.J.; Choi, N.K.; Lee, J.; Park, B.J. Zolpidem use and risk of fracture in elderly insomnia patients J. Prev. Med. Public Health 2012 , 45 , 219–226. [ CrossRef ] 66 Treves, N.; Perlman, A.; Kolenberg Geron, L.; Asaly, A.; Matok, I. Z-drugs and risk for falls and fractures in older adults—A systematic review and meta-analysis Age Ageing 2018 , 47 , 201–208. [ CrossRef ] [ PubMed ] 67 Bowie, M.W.; Slattum, P.W. Pharmacodynamics in older adults: A review Am. J. Geriatr. Pharmacother 2007 , 5 , 263–303. [ CrossRef ] 68 Guo, F.; Yi, L.; Zhang, W.; Bian, Z.J.; Zhang, Y.B. Association between Z drugs use and risk of cognitive impairment in middle-aged and older patients with chronic insomnia Front. Hum. Neurosci 2021 , 15 , 775144. [ CrossRef ] 69 Tseng, L.Y.; Huang, S.T.; Peng, L.N.; Chen, L.K.; Hsiao, F.Y. Benzodiazepines, z-Hypnotics, and risk of dementia: Special considerations of half-lives and concomitant use Neurotherapeutics 2020 , 17 , 156–164. [ CrossRef ]

Int. J. Environ. Res. Public Health 2022 , 19 , 11426 12 of 12 70 American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria ® for potentially inappropriate medication use in older adults J. Am. Geriatr. Soc 2019 , 67 , 674–694. [ CrossRef ] 71 Coupland, C.A.C.; Hill, T.; Dening, T.; Morriss, R.; Moore, M.; Hippisley-Cox, J. Anticholinergic drug exposure and the risk of dementia: A nested case-control study JAMA Intern. Med 2019 , 179 , 1084–1093. [ CrossRef ] 72 Borda, M.G.; Jaramillo-Jimenez, A.; Oesterhus, R.; Santacruz, J.M.; Tovar-Rios, D.A.; Soennesyn, H.; Cano-Gutierrez, C.A.; Vik-Mo, A.O.; Aarsland, D. Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer’s disease and Lewy body dementia Int. J. Geriatr. Psychiatry 2021 , 36 , 917–925. [ CrossRef ] 73 Saarelainen, L.; Tolppanen, A.M.; Koponen, M.; Tanskanen, A.; Sund, R.; Tiihonen, J.; Hartikainen, S.; Taipale, H. Risk of hip fracture in benzodiazepine users with and without Alzheimer disease J. Am. Med. Dir. Assoc 2017 , 18 , e 15–e 87. [ CrossRef ] 74 Taipale, H.; Tolppanen, A.M.; Koponen, M.; Tanskanen, A.; Lavikainen, P.; Sund, R.; Tiihonen, J.; Hartikainen, S. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease CMAJ 2017 , 189 , E 519–E 529. [ CrossRef ] 75 Rochon, P.A.; Vozoris, N.; Gill, S.S. The harms of benzodiazepines for patients with dementia CMAJ 2017 , 189 , E 517–E 518 [ CrossRef ] 76 Markota, M.; Rummans, T.A.; Bostwick, J.M.; Lapid, M.I. Benzodiazepine use in older adults: Dangers, management, and alternative therapies Mayo Clin. Proc 2016 , 91 , 1632–1639. [ CrossRef ] [ PubMed ] 77 Jang, Y.; Song, I.; Oh, I.-S.; Shin, J.-Y. Twelve-year trend in the use of zolpidem and physicians’ non-compliance with recommended duration: A Korean national health insurance database study Eur. J. Clin. Pharmacol 2019 , 75 , 109–117. [ CrossRef ] [ PubMed ] 78 Joung, K.I.; Shin, J.Y.; Cho, S.I. Features of anticholinergic prescriptions and predictors of high use in the elderly: Population-based study Pharmacoepidemiol. Drug Saf 2019 , 28 , 1591–1600. [ CrossRef ] 79 Rawla, P.; Sunkara, T.; Ofosu, A.; Gaduputi, V. Potassium-competitive acid blockers—Are they the next generation of proton pump inhibitors? World J. Gastrointest. Pharmacol. Ther 2018 , 9 , 63–68. [ CrossRef ] 80 Wu, C.Y.; Xiong, L.Y.; Ouk, M.; Rabin, J.S.; Herrmann, N.; Lanct ô t, K.L.; Kapral, M.K.; Law, M.; Cogo-Moreira, H.; Edwards, J.D.; et al. Gastric acid suppressants and cognitive decline in people with or without cognitive impairment Alzheimers Dement 2022 , 8 , e 12243. [ CrossRef ] [ PubMed ] 81 Clegg, A.; Young, J.B. Which medications to avoid in people at risk of delirium: A systematic review Age Ageing 2011 , 40 , 23–29 [ CrossRef ] [ PubMed ] 82 Lin, H.C.; Huang, K.T.; Lin, H.L.; Uang, Y.S.; Ho, Y.; Keller, J.J.; Wang, L.H. Use of gastric acid-suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: A population-based retrospective cohort study PLoS ONE 2021 , 16 , e 0249050. [ CrossRef ] 83 Maes, M.L.; Fixen, D.R.; Linnebur, S.A. Adverse effects of proton-pump inhibitor use in older adults: A review of the evidence Ther. Adv. Drug Saf 2017 , 8 , 273–297. [ CrossRef ]

Other Environmental Sciences Concepts:

[back to top]

Discover the significance of concepts within the article: ‘Potentially Inappropriate Medication Use in Patients with Dementia’. Further sources in the context of Environmental Sciences might help you critically compare this page with similair documents:

Pharmacotherapy, Korea, Older people, Chronic disease, Community, Clinical data, Cognitive function, Central nervous system, Chronic inflammation, Comparative studies, Potential harm, Gender difference, Mortality risk, Alzheimer's disease, European countries, South Korea, World Health Organization, Patient Monitoring, Clinical Practice, Female patient, Medication management, Cross-sectional study, Parkinson's disease, Cognitive impairment, Dementia, Alternative therapies, Cognitive decline, Systematic Review, Schizophrenia, Chronic disorder, Geriatric population, Institutional review board, Prospective cohort study, Population-based study, Drug therapy, Clinical information, Vulnerable Population, Declaration of Helsinki, Conflicts of interest, Statistical analyses, Hospitalization, Health outcome, Proton Pump Inhibitor, Ambulatory Patient, Memory decline, Incidence rate, Diagnosis and management, Public Health Policy, Clinical outcome, Polypharmacy, Geriatric Patient, Adverse drug event, Drug-Drug Interaction, Logistic regression, Alzheimer Disease, Study Limitation, Beers criteria, Medication reconciliation, Healthcare utilization, Zolpidem, Critical care medicine, Pharmacokinetic, Potentially inappropriate medication, Sex difference, Electronic medical record, Primary care setting, Benzodiazepine, Population-based cohort study, Univariate analysis, Gastrointestinal disorder, Mood Disorder, Geriatric, Parkinson's disease dementia, Real World Data, Medication therapy management, Disease comorbidities, Deprescribing, Informed consent statement, Patient factor, Longitudinal cohort study, Functional decline, Multiple comorbidities, Narrative review, Funding, Data availability statement, Fracture, Elderly patient, Older Population, Prescribing error, Medication use, Nested case-control study, International Classification of Disease, Nursing home residents, American Geriatrics Society, Insurance reimbursement, Ageing and health, Multivariate regression analysis, Older adult, EMR, Z drug, Formal analysis, Antipsychotic, Adverse health outcome, Anticholinergic, Review and editing, Antidepressant use, Data curation, Funding acquisition, Project administration, Baseline characteristic, H 2 RA, State-of-the-art review, Pharmacodynamic, Long-term mortality, Patients with dementia, Age-related change, Original draft preparation, Nationwide study, Regulatory Science, Evaluating risk, Consumption rate, Emergency department visit, Epidemiological feature, Primary care older patients, United state, Korean Older Adults, Anticholinergic prescriptions.